Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ocean Era Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This indicates a targeted prosecution effort for the company's biological and pharmaceutical innovations, focusing on a specific area of research.
The examination landscape is highly concentrated, with 1 distinct examiner and 1 distinct art unit. This structure suggests that the company's patent filings are currently focused within a single technical channel at the patent office. This centralization allows for a very specific interaction between the company and the examining body, which can be beneficial for establishing a clear technical narrative. The use of 1 distinct art unit further emphasizes the focused nature of the active portfolio.
KADE ARIANI is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This single action represents the total of 1 pending office action for the company. This indicates that the entirety of the company's active patent review is currently under the jurisdiction of this one examiner. The success of the company's current prosecution is therefore tied to the review of this specific individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIANI, KADE | 1 | 74.9% | +32.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843564 | DESIGNED MACROALGAE FEED PRODUCTS | ARIANI, KADE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843564 | DESIGNED MACROALGAE FEED PRODUCTS | ARIANI, KADE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843564 | DESIGNED MACROALGAE FEED PRODUCTS | ARIANI, KADE | 1651 | §102§103§112 | Non-Final OA | — | Pending | Sep 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOcean Era Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kade Ariani has the most, with 1 of Ocean Era Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.